Crizotinib
- PDF / 169,789 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 104 Downloads / 138 Views
1
S
Drug resistance: case report A 73-year-old woman developed crizotinib resistance during treatment of non-small cell lung cancer (NSCLC). The woman, who was recently diagnosed with stage IV ROS1-rearranged NSCLC, presented with refractory seizures and coma. She had been receiving crizotinib [dosage and route not stated] since 6 months, and had an excellent response at 2 months. A brain MRI revealed multiple intracranial metastasis with vasogenic oedema. A crizotinib-resistance was considered. The woman was treated with mannitol, unspecified steroids and anti-epileptics. But, her neurologic status remain unchanged. She was started on salvage therapy including bevacizumab for vasogenic oedema and lorlatinib. There was considerable improvement noted in her neurologic function and mental status after 48 hours. A repeat MRI revealed a slight interval decrease in the largest metastasis and associated oedema. At a 1 month follow-up, clinical improvement was noted. A brain MRI revealed a decrease in the sizes and/or resolution of all previously noted lesions and no new metastases or significant peritumoral oedema. Author comment: "We report a patient who developed secondary crizotinib-resistance and was successfully treated with lorlatinib." Franke A, et al. Lorlatinib Rescue Therapy for Life Threatening CNS Disease in Crizotinib-Resistant ROS1-Positive Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology 14 (Suppl.): S858-S859 abstr. P2.14-69, No. 10, Oct 2019. Available from: URL: http://doi.org/10.1016/j.jtho.2019.08.1854 [abstract] 803432549 USA
0114-9954/19/1778-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved
Reactions 9 Nov 2019 No. 1778
Data Loading...
